Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Non-Current Debt: 2020-2025

Historic Non-Current Debt for Oncology Institute (TOI) over the last 5 years, with Q3 2025 value amounting to $76.2 million.

  • Oncology Institute's Non-Current Debt fell 1676.04% to $76.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.2 million, marking a year-over-year decrease of 1676.04%. This contributed to the annual value of $93.1 million for FY2024, which is 726.16% up from last year.
  • Latest data reveals that Oncology Institute reported Non-Current Debt of $76.2 million as of Q3 2025, which was down 1676.04% from $75.0 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Non-Current Debt registered a high of $93.1 million during Q4 2024, and its lowest value of $73.9 million during Q1 2025.
  • For the 4-year period, Oncology Institute's Non-Current Debt averaged around $83.5 million, with its median value being $83.7 million (2023).
  • In the last 5 years, Oncology Institute's Non-Current Debt skyrocketed by 782.23% in 2023 and then tumbled by 1676.04% in 2025.
  • Oncology Institute's Non-Current Debt (Quarter) stood at $80.6 million in 2022, then grew by 7.7% to $86.8 million in 2023, then rose by 7.26% to $93.1 million in 2024, then fell by 18.19% to $76.2 million in 2025.
  • Its Non-Current Debt was $76.2 million in Q3 2025, compared to $75.0 million in Q2 2025 and $73.9 million in Q1 2025.